‘New drugs to prevent tuberculosis in the offing’

LONDON: Researchers have identified a novel regulatory mechanism, which when deactivated, results in the death of tuberculosis pathogen, an advance that could pave the way for newdrugs to prevent the life-threatening disease.

According to the World Health Organization (WHO), tuberculosis claimed over 1.3 million lives in 2016, said researchers from the University of Leicester in the UK.

The causative agent of tuberculosis, Mycobacterium tuberculosis, is a highly successful pathogen which can survive and grow in humans for decades, according to the study published in the journal Cell Reports.

M tuberculosis is a slow growing bacterium with a very thick and complex cell wall that is resistant tomany common antibiotics, requiring the development of new drugs and approaches in order to stop the deadly disease.

“M tuberculosis is a nasty pathogen which is very difficult to treat because of its unique biology,” said Galina Mukamolova from the University of Leicester.

“However, our research revealed weakness and vulnerable sides of this pathogen. We have shown that inactivation of just one protein can result in dramatic consequences.

“We can interfere into the very sophisticated mechanism for regulation of cell wall biosynthesis described in our study in order to kill M tuberculosis,” Mukamolova said.

The team examined a protein called protein kinase B (PknB) found in M tuberculosis and found thereasons why it is necessary for growth in the pathogen.

PknB has been known for many years and extensively studied by many scientific groups.

Previously, scientists showed that it was somehow involved in regulation of cell wall biosynthesis, however the precise mechanism was not clear.

“We have shown that CwlM, another protein required for M tuberculosis growth, is the main protein which is phosphorylated by PknB,” said Mukamolova.

“This function makes PknB indispensable for the growth of M tuberculosis. We found that two forms of CwlM (phosphorylated and non-phosphorylated) coexist in growing bacteria in different cellular compartments and may regulate different arms of the same process,” Mukamolova said.

The research suggests that inactivation of CwlM, for example by using novel drugs, would result indeath and lysis of M tuberculosis, researchers said.

This is an excellent target for new drug development, which is particularly important because of tuberculosis’ rising resistance to existing drugs, they said.

  • Related Posts

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    Patients for Patient Safety Foundation (PFPSF) Partners with CAHO to RollOut an Excellence Program New Delhi: Thanks to some well-meaning organizations, patients are going to be lord of all they…

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    BMJ Research Forum all set to mull over in Delhi on September 5 New Delhi: Research in healthcare in India is a dime a dozen. But the real question that…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

    Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    UP expands food, drug testing capacity across all 18 divisions

    UP expands food, drug testing capacity across all 18 divisions

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead